Phospho-PRKACA (Thr197) Antibody

What is PRKACA and why is phosphorylation at Thr197 significant?

PRKACA is the catalytic alpha subunit of cAMP-dependent protein kinase (PKA), a central enzyme in numerous cellular signaling pathways. Phosphorylation at Threonine 197 (Thr197) in the activation loop of PRKACA is essential for proper biological function and enzymatic activity. This phosphorylation represents a necessary step for the maturation and optimal biological activity of PKA . When phosphorylation at this site is impaired, the catalytic subunit can accumulate in an insoluble, unphosphorylated, and inactive form, as demonstrated in kinase-negative S49 mouse lymphoma cells . The phosphorylation status at this site serves as a critical indicator of PKA activation and signaling competency.

Which kinase is responsible for phosphorylating PRKACA at Thr197?

While PRKACA can autophosphorylate Thr197 when overexpressed in bacterial systems, in mammalian cells this phosphorylation is primarily mediated by PDK1 (phosphoinositide-dependent protein kinase 1). Studies have demonstrated that PDK1 expressed in 293 cells can efficiently phosphorylate and activate the catalytic subunit of PKA at Thr197 . This phosphorylation by PDK1 is rapid and notably insensitive to PKI (the highly specific heat-stable protein kinase inhibitor) . Mutation studies confirm the specificity of this interaction, as a mutant form of the catalytic subunit where Thr197 was replaced with Asp was not a substrate for PDK1 . This evidence suggests that PDK1, or one of its homologs, is a likely candidate for the in vivo phosphorylation and activation of PRKACA.

How can researchers verify the specificity of Phospho-PRKACA (Thr197) antibodies?

Verifying antibody specificity is crucial for reliable results when working with phospho-specific antibodies. Several approaches are recommended:

• Alkaline phosphatase (AP) treatment: Compare antibody reactivity in samples with and without AP treatment. A genuine phospho-specific antibody will show reduced or absent signal after phosphatase treatment .

• Mutant controls: Use samples expressing a Thr197Asp mutant, which should not be recognized by phospho-specific antibodies that exclusively detect the phosphorylated form .

• Kinase-dead controls: Compare with samples expressing kinase-dead PRKACA mutants (e.g., K72H), which should show reduced Thr197 phosphorylation .

• Activation experiments: Employ forskolin to activate cyclic AMP, which in turn activates PRKACA, as a positive control for phosphorylation .

These validation steps ensure that the observed signals truly represent the phosphorylated form of PRKACA rather than non-specific binding.

What are the key downstream targets of phosphorylated PRKACA?

Once phosphorylated at Thr197 and fully activated, PRKACA phosphorylates numerous downstream substrates involved in various cellular processes:

The phosphorylation of these targets mediates diverse cellular responses, including gene expression, cell survival, and metabolic regulation. Studies have demonstrated that PRKACA expression leads to approximately 4-fold increased CREB Ser133 phosphorylation compared to controls, with similarly increased phosphorylation observed at Ser63 in ATF1 .

How can Phospho-PRKACA (Thr197) antibodies be used to study disease mechanisms?

Phospho-PRKACA (Thr197) antibodies provide valuable insights into disease mechanisms across multiple conditions:

• Cancer research: These antibodies can identify aberrant PKA signaling in cancer. Research has shown that PRKACA overexpression mediates resistance to HER2-targeted therapy in breast cancer by restoring BAD phosphorylation and suppressing apoptosis . The kinase activity of PRKACA, dependent on Thr197 phosphorylation, is required for this therapeutic resistance.

• Endocrine disorders: Mutations in PRKACA have been identified in cortisol-producing adrenal adenomas . These mutations (such as p.Leu206Arg) disrupt the interaction between catalytic and regulatory subunits, resulting in constitutive PKA activity and increased phosphorylation of downstream targets like CREB and ATF1 .

• Comparative tissue analysis: Phospho-PRKACA (Thr197) antibodies enable comparison between normal and disease tissues, revealing alterations in PKA signaling that may contribute to pathogenesis.

• Therapeutic target validation: Measuring changes in PRKACA phosphorylation can help validate the efficacy of therapeutics targeting the PKA pathway.

What is the relationship between PRKACA Thr197 phosphorylation and mutant PKA activity?

Mutations in PRKACA can significantly alter the relationship between Thr197 phosphorylation and PKA activity. The p.Leu206Arg mutation, identified in cortisol-producing adrenal adenomas, provides a notable example:

• Structural impact: This mutation disrupts the interaction between PRKACA and its regulatory subunit PRKAR1A. The regulatory subunit normally binds to PRKACA catalytic cleft via a pseudosubstrate sequence (R-R-G-A-I), with the isoleucine fitting into a hydrophobic cleft formed by Leu206 and Leu199 .

• Biochemical consequences: When the p.Leu206Arg mutation is present, immunoprecipitation experiments show no detectable PRKAR1A pulled down with PRKACA L206R, while wild-type PRKACA robustly binds PRKAR1A .

• Functional outcomes: The unbound PRKACA L206R results in constitutive kinase activity, leading to approximately 4-fold increased phosphorylation of CREB at Ser133 and ATF1 at Ser63 compared to wild-type PRKACA .

• Clinical correlations: Adenomas with PRKACA mutations present distinct clinical features, being significantly smaller (28.7 ± 7.3 mm versus 39.2 ± 15.9 mm) and occurring at younger ages (45.3 ± 13.5 versus 52.5 ± 11.9 years) compared to adenomas without these mutations .

This demonstrates how mutations can fundamentally alter the regulation of PRKACA activity while maintaining Thr197 phosphorylation, resulting in pathological consequences.

How do PDK1-mediated and autophosphorylation mechanisms differ for PRKACA Thr197?

Two distinct mechanisms can lead to phosphorylation of PRKACA at Thr197:

Research has demonstrated that PDK1 expressed in 293 cells rapidly phosphorylates and activates the catalytic subunit of PKA at Thr197, and this phosphorylation is insensitive to PKI . The heterologous mechanism of PDK1-mediated phosphorylation likely represents the physiologically relevant pathway for PRKACA activation in most cellular contexts.

What methodological approaches are most effective for quantifying Phospho-PRKACA (Thr197) in clinical samples?

Several methodological approaches can be employed for quantifying Phospho-PRKACA (Thr197) in clinical samples, each with distinct advantages:

• Reverse Phase Protein Array (RPPA): This technique serves as a powerful tool particularly for quantitative proteomics from finite amounts of materials such as patient tissues and is especially useful for post-translational modifications profiling . RPPA allows parallel multi-omics profiling incorporating other data on the same set of samples and has shown great interexperimental reproducibility with significant correlation to pathological markers in tissues like melanoma and lung cancer .

• Western Blotting: Traditional western blotting provides size verification and semi-quantitative assessment of Phospho-PRKACA levels. The method benefits from widespread availability but requires larger sample volumes than RPPA.

• Colorimetric Cell-Based ELISA: Commercial kits like the PKA Alpha/Beta Cat Phospho-Thr197 Colorimetric Cell-Based ELISA offer high sensitivity and specificity for detecting phosphorylated PKA alpha/beta at threonine 197 in cell lysates and tissue samples . These assays provide reliable and reproducible results across various experimental settings.

• Immunohistochemistry: This approach allows visualization of Phospho-PRKACA distribution within tissues and has been used to show increased staining of downstream targets (e.g., CREB Ser133-P) in PRKACA-mutant tumors compared to wild-type adenomas .

Each method should be selected based on sample availability, required sensitivity, and the specific research questions being addressed.

What controls are essential when using Phospho-PRKACA (Thr197) antibodies in experimental designs?

Rigorous experimental design requires appropriate controls to ensure reliable interpretation of results:

• Positive controls:

  • Lysates from cells treated with PKA activators (e.g., forskolin, which activates cyclic AMP)

  • Recombinant phosphorylated PRKACA protein (commercially available)

  • Cells expressing constitutively active PRKACA mutants

• Negative controls:

  • Alkaline phosphatase-treated samples to remove phosphorylation

  • Lysates from cells treated with PKA inhibitors

  • Non-phosphorylatable mutant (e.g., Thr197Ala)

• Specificity controls:

  • Phospho-mimetic mutant (e.g., Thr197Asp), which should not be recognized by phospho-specific antibodies

  • Kinase-dead PRKACA mutant (K72H), which fails to restore phosphorylation of downstream targets

  • Peptide competition controls

• Loading and normalization controls:

  • Total PRKACA antibody on parallel blots or after stripping

  • Housekeeping proteins (e.g., GAPDH, β-actin)

  • Total protein staining methods

The search results specifically highlight the importance of comparing phosphorylation in wild-type versus mutant conditions, demonstrating that kinase-dead PRKACA-KD fails to restore BAD phosphorylation, confirming that kinase activity is required for this effect .

How should sample preparation be optimized to preserve PRKACA phosphorylation status?

Preserving the in vivo phosphorylation status of PRKACA requires careful attention to sample preparation:

• Rapid processing:

  • Minimize time between sample collection and processing

  • Flash-freeze tissues in liquid nitrogen immediately after collection

  • Use pre-chilled buffers and equipment to prevent phosphatase activity

• Phosphatase inhibition:

  • Include phosphatase inhibitor cocktails in all lysis and extraction buffers

  • Use specific inhibitors targeting serine/threonine phosphatases

  • Consider fresh inhibitors for each experiment as some have limited stability

• Tissue-specific considerations:

  • For fresh frozen (FF) tissues: Homogenize in buffer containing protease and phosphatase inhibitors

  • For formalin-fixed paraffin-embedded (FFPE) tissues: Use specialized extraction buffers and protocols designed for phosphoprotein recovery

  • For cell cultures: Rapidly lyse cells directly in plates to minimize processing time

• Buffer compatibility:

  • Ensure lysis buffers are compatible with downstream applications

  • The search results mention using "lysis buffer compatible with alkaline phosphatase (AP) treatment" that differs from conventional procedures

  • Avoid milk-based blockers which contain phosphatases

These precautions help maintain the native phosphorylation state of PRKACA and prevent artifactual changes during sample handling.

What are the optimal conditions for detecting Phospho-PRKACA (Thr197) in different applications?

Optimization conditions vary across different experimental applications:

• Western blotting:

  • Use 10-12% SDS-PAGE for optimal resolution of PRKACA (~40 kDa)

  • Block in 5% BSA rather than milk (which contains phosphatases)

  • Dilute primary antibody according to manufacturer recommendations (typically 1:1000)

  • Incubate overnight at 4°C for maximal sensitivity

  • Use PVDF membranes for better retention of phosphoproteins

• Immunohistochemistry/Immunofluorescence:

  • Optimize antigen retrieval (typically heat-induced in citrate buffer)

  • Consider signal amplification systems for low abundance targets

  • Use tissue sections of consistent thickness (4-5 μm recommended)

  • Include positive control tissues with known high PRKACA phosphorylation

• RPPA (Reverse Phase Protein Array):

  • Follow standardized protocols for sample spotting and processing

  • Include dilution series for accurate quantification

  • Implement rigorous antibody validation, as the quality of results depends heavily on antibody specificity

  • Consider AP treatment as an independent factor for rapid phospho-antibody selection

• Cell-based ELISAs:

  • Follow manufacturer's recommendations for cell density and fixation

  • Optimize primary antibody concentration through titration

  • Ensure consistent washing to minimize background

Each application requires specific optimization to achieve maximal sensitivity and specificity for detecting Phospho-PRKACA (Thr197).

What factors influence the interpretation of Phospho-PRKACA (Thr197) levels in experimental systems?

Accurate interpretation of Phospho-PRKACA (Thr197) levels requires consideration of several factors:

• Relationship to total PRKACA:

  • Always measure total PRKACA levels alongside phosphorylated form

  • Calculate the ratio of phospho-PRKACA to total PRKACA

  • Research shows that PRKACA expression levels positively correlate with the extent of downstream effects

• Context of upstream regulators:

  • Consider the status of PDK1 activity

  • Evaluate cAMP levels and activators in the system

  • Assess regulatory subunit (e.g., PRKAR1A) expression and binding

• Downstream target activation:

  • Verify functional consequences by measuring phosphorylation of canonical PKA targets

  • Research demonstrates that phosphorylation of CREB at Ser133 and ATF1 at Ser63 serves as reliable indicators of PRKACA activity

  • BAD phosphorylation at ser112 and ser136 provides another readout of functional PRKACA activity

• Experimental manipulations:

  • Account for effects of treatments that may alter PKA signaling

  • For example, lapatinib treatment diminishes BAD phosphorylation, which can be restored by PRKACA expression

  • Forskolin pre-treatment activates endogenous PRKACA, providing a positive control

• Mutational status:

  • Mutations in PRKACA (e.g., L206R) can significantly alter its regulation while maintaining phosphorylation

  • These mutations disrupt regulatory subunit binding, resulting in constitutive activity regardless of upstream signals

What are common causes of false negative results when detecting Phospho-PRKACA (Thr197)?

False negative results can arise from various technical issues:

• Phosphatase activity during sample preparation:

  • Inadequate phosphatase inhibitors in lysis buffers

  • Delayed processing allowing endogenous phosphatases to act

  • Use of milk-based blockers containing phosphatases

  • Solution: Include comprehensive phosphatase inhibitor cocktails and process samples rapidly

• Epitope masking:

  • Improper fixation conditions obscuring the phospho-epitope

  • Insufficient antigen retrieval in fixed tissues

  • Protein-protein interactions blocking antibody access

  • Solution: Optimize fixation protocols and antigen retrieval methods

• Antibody sensitivity issues:

  • Insufficient primary antibody concentration

  • Degraded antibody quality

  • Poor affinity for the specific phospho-epitope

  • Solution: Titrate antibody, use fresh aliquots, consider alternative antibodies

• Low abundance target:

  • PRKACA may be expressed at low levels in certain tissues

  • Phosphorylation may be transient or low stoichiometry

  • Solution: Consider enrichment steps or signal amplification methods

• Technical limitations:

  • Inadequate transfer in Western blotting

  • Improper blocking conditions

  • Suboptimal detection reagents

  • Solution: Optimize each step of the protocol with appropriate controls

How can researchers differentiate between changes in PRKACA expression versus phosphorylation status?

Distinguishing between changes in total PRKACA expression versus alterations in phosphorylation status requires specific experimental approaches:

• Parallel detection methods:

  • Use antibodies against total PRKACA alongside phospho-specific antibodies

  • Run identical samples on parallel blots or sequentially probe the same membrane

  • Calculate the ratio of phospho-PRKACA to total PRKACA

• Quantitative analysis:

  • Employ quantitative methods such as RPPA, which shows excellent reproducibility

  • Use internal controls and standard curves for accurate quantification

  • Ensure signal detection remains in the linear range

• Experimental manipulations:

  • Compare samples with equivalent total PRKACA but different activating conditions

  • Use phosphatase treatment to remove phosphorylation while preserving total protein

  • Employ expression systems with controlled PRKACA levels but variable activation

• Genetic approaches:

  • Compare wild-type to phospho-mimetic (T197D) or non-phosphorylatable (T197A) mutants

  • Use inducible expression systems to control total protein levels

  • The research demonstrates that expression of wild-type versus kinase-dead PRKACA can help differentiate activity-dependent effects

This multi-faceted approach enables researchers to determine whether observed changes result from altered expression, phosphorylation, or both.

What strategies can overcome challenges in detecting Phospho-PRKACA (Thr197) in fixed tissue samples?

Fixed tissue samples present unique challenges for phospho-protein detection:

• Optimized antigen retrieval:

  • Test multiple antigen retrieval methods (heat-induced vs. enzymatic)

  • Optimize pH, temperature, and duration of retrieval

  • Consider dual retrieval methods for challenging samples

• Signal amplification:

  • Implement tyramide signal amplification or other amplification systems

  • Use polymer-based detection systems for enhanced sensitivity

  • Consider longer primary antibody incubation (overnight at 4°C)

• Fixation considerations:

  • Minimize fixation time to prevent excessive cross-linking

  • Use phosphatase inhibitors during fixation when possible

  • Compare results between fresh frozen and FFPE samples when available

  • Research shows both fresh frozen (FF) and formalin-fixed paraffin-embedded (FFPE) tissues can be used for phospho-protein profiling

• Alternative approaches:

  • Consider proximity ligation assays for enhanced specificity

  • Use multiplexed immunofluorescence to correlate with other markers

  • Implement laser capture microdissection to isolate specific cell populations

• Validation strategies:

  • Include positive control tissues with known high phosphorylation

  • Use tissues from experimental models with activated PKA signaling

  • Correlate IHC results with other methods like Western blotting

These strategies can help overcome the inherent challenges of phospho-epitope detection in fixed tissues.

How should researchers address inconsistent results between different detection methods?

Inconsistencies between detection methods require systematic troubleshooting:

• Method-specific considerations:

  • Western blotting: May be affected by transfer efficiency and membrane binding

  • IHC/IF: Subject to fixation artifacts and antigen retrieval variability

  • RPPA: Highly dependent on antibody specificity and sample printing

  • ELISA: May have different sensitivity to interfering substances

• Sample preparation differences:

  • Each method may require different lysis buffers or processing steps

  • Phosphatase activity may vary between protocols

  • Protein denaturation conditions differ across methods

• Antibody behavior:

  • The same antibody may perform differently across methods

  • Some antibodies work well for denatured proteins but poorly for native proteins

  • Batch-to-batch variability can affect results

• Quantification approach:

  • Standardize quantification methods across techniques

  • Use absolute quantification with standard curves when possible

  • Implement consistent normalization strategies

• Resolution strategy:

  • Implement orthogonal validation using complementary techniques

  • Consider phosphatase treatment controls across all methods

  • Use genetic models (knockout/knockdown) to validate specificity

  • Mutant forms of PRKACA (e.g., kinase-dead K72H) can serve as important controls

The research highlights the importance of such validation, showing that phosphorylation of BAD at ser112 and ser136 is dependent on catalytically active PRKACA, confirming the specificity of the observed phosphorylation .

How can researchers quantitatively assess changes in PRKACA phosphorylation across experimental conditions?

Quantitative assessment of PRKACA phosphorylation requires rigorous analytical approaches:

These quantitative approaches enable rigorous comparison of PRKACA phosphorylation across experimental conditions.

What correlations exist between PRKACA Thr197 phosphorylation and disease progression?

Research has revealed several important correlations between PRKACA Thr197 phosphorylation and disease:

• Cancer:

  • PRKACA overexpression and consequent signaling promotes resistance to HER2-targeted therapy in breast cancer

  • This resistance mechanism operates through restoration of BAD phosphorylation and suppression of apoptosis

  • Similar mechanisms involving PIM1 and PIM2, which also phosphorylate BAD, suggest a common resistance pathway

• Endocrine disorders:

  • Mutations in PRKACA (particularly L206R) are found in cortisol-producing adrenal adenomas

  • These mutations prevent binding of regulatory subunits, leading to constitutive activation

  • Clinical correlations show that adenomas with PRKACA mutations are significantly smaller (28.7 ± 7.3 mm versus 39.2 ± 15.9 mm) and present at younger ages (45.3 ± 13.5 versus 52.5 ± 11.9 years)

  • They are also significantly associated with overt Cushing syndrome (13/16 with mutations versus 16/39 without)

• Tissue-specific findings:

  • Research using RPPA on both fresh frozen and FFPE samples has demonstrated significant correlation between phospho-protein profiles and pathological markers in melanoma and lung cancer tissues

  • These correlations generate meaningful data that match clinical features

These findings suggest that altered PRKACA phosphorylation and activity contribute to disease pathogenesis and may serve as biomarkers for disease progression or treatment response.

How does PRKACA Thr197 phosphorylation relate to the activation of other PKA subunits?

The relationship between PRKACA Thr197 phosphorylation and other PKA subunits is complex:

• Regulatory subunit interactions:

  • Phosphorylation at Thr197 occurs within the catalytic cleft of PRKACA

  • The regulatory subunit (primarily PRKAR1A in human adrenal tissue) binds to this catalytic cleft via a pseudosubstrate sequence (R-R-G-A-I)

  • When PRKACA is bound to regulatory subunits, it remains inactive despite Thr197 phosphorylation

  • The p.Leu206Arg mutation disrupts this interaction, preventing regulatory subunit binding and resulting in constitutive activity

• Holoenzyme composition:

  • The PKA holoenzyme typically consists of two catalytic subunits (e.g., PRKACA) and a regulatory subunit dimer

  • Thr197 phosphorylation is required for proper catalytic activity but is not sufficient for activation in the presence of regulatory subunits

  • cAMP binding to regulatory subunits is needed to release and activate the phosphorylated catalytic subunits

• Isoform-specific regulation:

  • PRKACA is the most highly expressed catalytic isoform in human adrenal tissue

  • Different tissues may express various isoforms of both catalytic and regulatory subunits

  • Thr197 is conserved across catalytic isoforms, suggesting a common activation mechanism

• Cross-regulation:

  • Activated PRKACA can potentially influence the phosphorylation and function of other PKA subunits

  • Regulatory feedback loops may exist between different PKA complexes

Understanding these relationships is crucial for interpreting the broader implications of PRKACA Thr197 phosphorylation in PKA signaling networks.

What is the significance of PRKACA Thr197 phosphorylation in therapeutic resistance mechanisms?

PRKACA Thr197 phosphorylation plays a critical role in therapeutic resistance mechanisms:

• HER2-targeted therapy resistance:

  • PRKACA overexpression mediates resistance to anti-HER2 therapies (trastuzumab and lapatinib) in breast cancer

  • This resistance mechanism operates through BAD phosphorylation, which prevents the inhibitory influence of BAD on BCL-2 and BCL-XL, thereby promoting anti-apoptotic activities

  • The kinase activity of PRKACA, dependent on Thr197 phosphorylation, is required for this resistance mechanism

• Mechanistic insights:

  • PRKACA expression restores BAD phosphorylation at ser112 and ser136 in the presence of lapatinib or trastuzumab

  • This restoration occurs without reactivating MAPK or PI3K signaling pathways

  • Expression of kinase-dead PRKACA mutant (K72H) fails to rescue cells from lapatinib treatment or restore BAD phosphorylation

• Physiological relevance:

  • Activation of endogenous PRKACA by forskolin (which activates cyclic AMP) results in resistance to lapatinib treatment and restoration of BAD phosphorylation

  • This confirms that the phenotypes observed with exogenous PRKACA expression also occur upon activation of endogenous PRKACA

• Additional resistance factors:

  • PIM1 and PIM2, which also scored in screens for resistance factors, phosphorylate BAD in a similar manner

  • PIM1 expression rescues HER2-amplified cells from lapatinib and trastuzumab treatment

  • This suggests convergence on BAD phosphorylation as a common resistance mechanism

These findings highlight the potential of targeting PRKACA or its downstream effects to overcome therapeutic resistance in cancer treatment.